Genmab License Agreement (Details) - Genmab A/S - License $ in Millions |
Feb. 14, 2025
USD ($)
target
license
|
Mar. 31, 2025
USD ($)
|
|---|---|---|
| Disaggregation of Revenue [Line Items] | ||
| Maximum number of undisclosed targets to research products | target | 3 | |
| Maximum number of commercial licenses for worldwide development and commercialization of products | license | 3 | |
| Upfront payment | $ 15.0 | $ 15.0 |
| Maximum additional potential option exercise fee | 15.0 | |
| Potential additional development and sales milestone | $ 234.0 |
| X | ||||||||||
- Definition Contract With Customer, Maximum Number Of Licenses For Development And Commercialization Of Products No definition available.
|
| X | ||||||||||
- Definition Contract With Customer, Maximum Number Of Undisclosed Targets To Research Products No definition available.
|
| X | ||||||||||
- Definition Revenue From Contract With Customer, Potential Additional Development, Regulatory And Sales Milestone Payments No definition available.
|
| X | ||||||||||
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount No definition available.
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|